INTRODUCTION {#s1}
============

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury with an estimated annual economic burden considerable in both the United States and Europe ([@R1]). For the detection of fat in the liver in patients without any clinical suspect of liver inflammation, noninvasive methods are indicated. Conventional B-mode ultrasound (US) is the imaging modality most widely used. It gives a subjective estimate of the entity of fatty infiltration in the liver and has a low sensitivity for the detection of mild steatosis ([@R2],[@R3]).

MRI-derived proton density fat fraction (PDFF) is a technique that accurately quantifies the hepatic fat content and has been accepted as an alternative to the histological assessment of liver steatosis in patients with NAFLD ([@R4]--[@R8]). MRI-PDFF is not influenced by confounding factors, including body weight, and is operator independent ([@R4],[@R9],[@R10]). However, it may have applicability limitations, and the availability and costs should be taken into account when used for screening purpose.

The controlled attenuation parameter (CAP) is a tool that noninvasively quantifies the amount of fat in the liver ([@R11]). The performance of the CAP in detecting and quantifying steatosis has been assessed in cohort of patients and in a meta-analysis with individual patient\'s data ([@R12]). A dedicated device, which does not allow the morphological assessment of the liver, is needed. Recently, techniques for the quantification of liver steatosis have been developed and implemented in the US systems.

The primary aim of this study was to investigate the diagnostic performance of a new US technique for the detection of liver steatosis in adult subjects by comparing the results to that obtained with the CAP and by using MRI-PDFF as the reference standard. The secondary aim was to assess the concordance of ATI and MRI-PDFF in grading liver steatosis.

METHODS {#s2}
=======

Design overview {#s2-1}
---------------

This was a prospective study. From March to November 2018, consecutive adult subjects potentially at risk of liver steatosis, i.e., overweight or obese subjects and subjects with metabolic syndrome and/or diabetes who complied with the study protocol, were prospectively enrolled at the outpatient clinics of 3 centers in Pavia, Italy. Moreover, to obtain a reliable threshold for the detection of liver steatosis, healthy controls were enrolled as well. The patients were enrolled from the outpatient clinics of the department of medical sciences and infectious diseases, "Fondazione IRCCS Policlinico San Matteo"; the department of applied health sciences, "Azienda di Servizi alla Persona Santa Margherita"; the unit of internal medicine and endocrinology, "ICS Maugeri." The healthy controls were hospital workers who were regularly followed with laboratory investigations. All of them had normal laboratory values and none of them had a history of liver disease or was using medication. All the enrolled subjects, including the healthy controls, had an alcohol intake less than 20 g/d.

Exclusion criteria were history of significant alcohol intake within 2 years of recruitment, secondary causes of liver steatosis, viral or autoimmune hepatitis, infection with human immunodeficiency virus, and genetic disorders. A total of 141 subjects were considered eligible for the study; of these, 129 participants complied with the study protocol.

All patients underwent clinical evaluation, anthropometric examination, and fasting biochemical tests. Each subject underwent B-mode US imaging together with the US quantification of liver steatosis, and CAP and stiffness assessment with the FibroScan system. All these studies were conducted on the same day. MRI-PDFF was performed within a week.

The examinations with the US and the FibroScan systems were performed at the department of medical sciences and infectious diseases, "Fondazione IRCCS Policlinico San Matteo," by 2 expert operators (G.F. and L.M.) who were blinded to biochemical data and MRI-PDFF results. Each subject was studied by a single operator who performed first the US assessment of liver steatosis both in B-mode and with the attenuation imaging (ATI) technique of the US system, and thereafter the fat and stiffness assessment with the FibroScan. MRI-PDFF was performed at the radiology unit of "Fondazione IRCCS Policlinico San Matteo" by an expert radiologist (MVR) who was blinded to biochemical data and to the other imaging results.

The study protocol was approved by the Ethics Committee of Fondazione IRCCS Policlinico San Matteo (P-20170022247) and it conformed to the ethical guidelines of the 1975 Declaration of Helsinki. Informed written consent was obtained from all participants.

Attenuation imaging {#s2-2}
-------------------

ATI is an FDA approved technique, implemented in the Aplio i800 US system (Canon Medical Systems, formerly Toshiba Medical Systems, Otawara, Japan), which quantifies the US attenuation in the tissue within a large sample measurement and using a real-time color mapping. The raw data of the backscattered US signals are used for the quantification; thus, the measurement is not affected by the postprocessing of the acquired data or by the settings of the US system. ATI calculates the attenuation coefficient in decibel per centimeter per megahertz (dB/cm/MHz), filtering out vessels or strong artifacts. The region of interest (ROI) has a length of 100 mm, with an upper and lower width of 45 mm and 80 mm, respectively, covering around 70% of the B-mode image. The measurement box has a fixed size of 30 × 30 mm when placed in the middle of the image. In the ROI, the degree of attenuation of the US signal is color coded with light blue colors that are mixed with orange shades in case of high attenuation (see Figure, Supplemental Digital Content 1, <http://links.lww.com/CTG/A95>, which shows the color map of the ATI technique). By using the trackball of the US system, the operator can freely move both the ROI and the measurement box, choosing the area where to perform the measurement. A dark orange area, which usually appears in the upper edge of the ROI, or dark blue areas posterior to blood vessels were not included in the measurement box because they were deemed to be artefacts.

The ATI repeatability (in terms of both intraobserver and interobserver agreement) was assessed in a series of 30 subjects enrolled only for that purpose (13 males and 17 females; mean age, 48.4 \[13.7\] years; mean body mass index \[BMI\], 24.6 \[4.8\] kg/m^2^). Each subject was scanned by the 2 physicians who performed the examinations in random order. Each operator performed 2 sets of 5 ATI acquisitions in the same subject, 15 minutes apart. The 2 operators were unaware of each other results. The overall agreement was 0.94 (95% confidence interval, 0.90--0.97). The intraobserver agreement was 0.91 (0.84--0.97) for rater 1 and 0.98 (0.97--0.99) for rater 2. The interobserver agreement was 0.92 (0.86--0.97).

Examinations of both ATI and CAP were conducted following a fast of at least 6 hours. The acquisitions were obtained in the right lobe of the liver, through intercostal spaces and with the patient lying in the supine position. The median value of 5 consecutive measurements, together with the interquartile range (IQR), was used for statistical analyses. The entire examination with ATI lasted approximately 1 minute per patient.

CAP and stiffness assessment {#s2-3}
----------------------------

CAP was obtained using the FibroScan 502 Touch system. The 3.5 MHz M probe was used when the skin to liver capsule distance, estimated with US, was ≤25 mm, otherwise the 2.5 MHz XL probe was used. The FibroScan estimates both liver stiffness in kiloPascal (kPa) and liver attenuation coefficient in decibel/meter (dB/m). The principles of CAP have been described elsewhere ([@R11]). The FibroScan computes CAP only when the associated liver stiffness measurement (LSM) is valid and it uses the same signal as the one used to measure liver stiffness. As recommended, only LSM with 10 validated measurements and an IQR/median (IQR/M) \< 30% were considered reliable ([@R13]). There are no recommendations for successful CAP measurement.

MRI-derived proton density fat fraction {#s2-4}
---------------------------------------

MRI was performed with a 1.5 T system (Magnetom Aera; Siemens Healthineers, Erlangen, Germany) using an 18-channel surface coil in combination with a 32-channel coil. For each examination, a noncontrast, complex-based gradient-echo 3D sequence, which provides whole-liver coverage, was obtained ([@R4],[@R14]). It includes several features that compensate for confounding effects: low flip angle for reducing T1 effects, a multifat peak model for robust lipid estimation and multiple echo acquisitions for R2\*/T2\* estimation and correction ([@R5],[@R15]--[@R18]). The single breath-hold sequence with 6 echoes was performed and provided volumetric PDFF. Digital Imaging and COmmunications in Medicine (DICOM) image files for MRI sequences were transferred to a secure local computer system.

The detection of liver steatosis (S \> 0), significant steatosis (S \> 1), and severe steatosis (S \> 2) were defined by MRI-PDFF ≥5%, ≥16.3%, and ≥21.6%, respectively ([@R5],[@R19]).

Statistical analysis {#s2-5}
--------------------

Power of the study and sample size estimation: A total sample size of 120 subjects (which includes 60 subjects with the disease) achieves 90% power to detect a change in sensitivity from 0.75 to 0.90 using a one-sided binomial test. The target significance level is 0.05 and the prevalence of the disease is 0.5.

Descriptive statistics were produced for demographic characteristics for this study sample of patients. The Shapiro--Wilk test was used to test the normal distribution of quantitative variables. When quantitative variables were normally distributed, the results were expressed as the mean value and SD, otherwise median and IQR (25th−75th percentile) were reported. Qualitative variables were summarized as counts and percentages. Univariate Pearson\'s r coefficient was used to test correlations between ATI and MRI-PDFF, CAP and MRI-PDFF, and ATI and CAP. The correlations were categorized as follows: 0.00 to 0.25 none or slight; 0.25 to 0.50 fair to moderate; 0.50 to 0.75 moderate to good; 0.75 to 1.00 almost perfect ([@R20]). Linear regression was used for multivariate models to assess the association between ATI or CAP and steatosis, age, gender, and BMI. The diagnostic performance of ATI or CAP was assessed by using receiver operating characteristic (ROC) curves and the area under the ROC (AUROC) curve analysis. The optimal threshold was determined using the Youden index to maximize sensitivity and specificity ([@R21]). Comparisons of the AUROCs were done using the method described by DeLong et al. ([@R22]) for correlated data. Concordance between ATI and MRI-PDFF in grading liver steatosis was assessed by means of Cohen kappa coefficient.

Data analysis was performed with STATA statistical package (release 15, 2017; Stata Corporation, College Station, TX) and MedCalc (MedCalc Statistical Software version 18.11) (MedCalc Software bvba, Ostend, Belgium).

The study was conducted and written according to the Standards for Reporting of Diagnostic Accuracy (STARD) initiative ([@R23]).

RESULTS {#s3}
=======

One hundred twenty-nine subjects (66 males and 63 females; mean age, 50.6 \[15.3\] years; mean BMI, 29.5 \[5.2\] kg/m^2^) were enrolled in the study. Of the 123 patients with MRI-PDFF results, 87 subjects (50 males and 37 females; mean age, 53.6 \[13.5\] years; mean BMI, 30.7 \[5.3\] kg/m^2^) had liver steatosis and 36 (13 males and 23 females; mean age, 42.3 \[15.4\] years; mean BMI, 27.2 \[3.7\] kg/m^2^) were without steatosis. The prevalence of liver steatosis was 70.7%. Fifteen subjects without steatosis (7 males and 8 females; mean age, 35.7 \[11.2\] years; mean BMI, 23.3 \[1.7\] kg/m^2^) were healthy controls. Four subjects did not undergo MRI-PDFF evaluation due to claustrophobia. In 2 healthy subjects, MRI-PDFF was not diagnostic for water/fat swapping. This artefact determines an abnormally high fat measurement (over 90%) and occur when there is a very low amount of fat in the liver ([@R14]). There was 1 failure with ATI measurement whereas none failure or unreliable result was observed with the FibroScan system. The flow diagram of the study is shown in Figure [1](#F1){ref-type="fig"}. CAP and LSMs were assessed with the M probe in 73 (56.6%) subjects and the XL in 56 (43.4%) subjects. The baseline characteristics of the study cohort are summarized in Table [1](#T1){ref-type="table"}. Whereas 85.3% of subjects with MRI-PDFF ≥5% had a liver stiffness value up to 7 kPa, i.e., no fibrosis/mild fibrosis, only 13 subjects (9.3%) had stiffness values above 10 kPa, i.e., in the range of severe fibrosis. All ATI values were obtained with an IQR/M \< 30%, and it was below 25% in 95% of cases. Figure [2](#F2){ref-type="fig"} shows the median values of ATI and CAP for each steatosis grade as defined by MRI-PDFF.

![Flow chart of the study. CAP measurements: n = 125; ATI measurements: n = 124. ATI, attenuation imaging; CAP, controlled attenuation parameter; PDFF, proton density fat fraction.](ct9-10-e00081-g001){#F1}

###### 

Baseline characteristics, stratified by nonalcoholic fatty liver disease status, of the 123 subjects with MRI-PDFF results available

![](ct9-10-e00081-g002)

![MRI-PDFF steatosis grade: \<5%: S0 (n = 36), 5%: S1 (n = 65), 16.3%: S2 (n = 8), 21.6%: S3 (n = 14). Median values and interquartile range (in parenthesis) for each fibrosis stage and *P* values of differences between consecutive grades are given. The central box represents values from the lower to upper quartile (25--75 percentile). The middle line represents the median. A line extends from the minimum to the maximum value (range), excluding "outside" values, which are displayed as separate points. The difference among steatosis grade was evaluated with one-way analysis of variance by ranks (Kruskal--Wallis test) adjusted with *post hoc* Bonferroni test. ATI, attenuation imaging; CAP, controlled attenuation parameter; CI, confidence interval; PDFF, proton density fat fraction.](ct9-10-e00081-g003){#F2}

Correlation analysis {#s3-1}
--------------------

The univariate analysis showed a high correlation of ATI with MRI-PDFF (r = 0.81, *P* \< 0.0001). The correlation of CAP with MRI-PDFF and with ATI, respectively, was moderate (r = 0.65, *P* \< 0.0001; and r = 0.61, *P* \< 0.0001) (Figure [3](#F3){ref-type="fig"}) (see Figure, Supplemental Digital Content 2, <http://links.lww.com/CTG/A96>, which shows the correlation of CAP with ATI). The correlation of ATI with MRI-PDFF was significantly higher than the correlation of CAP with MRI-PDFF (*P* = 0.007). In multivariate analysis, the correlation of ATI or CAP with MRI-PDFF was not affected by age, gender, BMI, liver stiffness, and skin-to-liver capsule distance (see Table, Supplemental Digital Content 3, <http://links.lww.com/CTG/A97>; see Table, Supplemental Digital Content 4, <http://links.lww.com/CTG/A98> showing the results of the multivariate analysis).

![The scatter plots of the ATI and the CAP on the vertical axis vs MRI-PDFF values on the horizontal axis. ATI, attenuation imaging; CAP, controlled attenuation parameter; PDFF, proton density fat fraction.](ct9-10-e00081-g004){#F3}

Accuracy analysis {#s3-2}
-----------------

The AUROCs of ATI were 0.91 (0.84--0.95; *P* \< 0.0001) at a cut point of 0.63 dB/cm/MHz for the detection of S \> 0 liver steatosis and 0.95 (0.89--0.98; *P* \< 0.0001) at a cut point of 0.72 dB/cm/MHz for the detection of S \> 1 liver steatosis. A cutoff of 0.59 dB/cm/MHz ruled out liver steatosis (S \> 0) with a sensitivity of 90.7% (82.5--95.9) whereas a cutoff of 0.70 dB/cm/MHz ruled in liver steatosis with a specificity of 97.2% (85.5--99.9). The AUROCs of CAP were 0.85 (0.77--0.91; *P* \< 0.0001) at a cut point of 258 dB/m for the detection of S \> 0 liver steatosis and 0.88 (0.81--0.93; *P* \< 0.0001) dB/m at a cut point of 304 dB/m for the detection of S \> 1 liver steatosis. The skin-to-liver capsule distance or the liver stiffness did not affect the performance of ATI.

The diagnostic performance of ATI and CAP is reported in Table [2](#T2){ref-type="table"}. Because of the small number of patients in this pilot study, the accuracy of ATI or CAP for S0-S1-S2 vs S3 (S \> 2) was not evaluated. Both ATI and CAP performed better at ruling-out than at ruling-in the disease.

###### 

Resulting clinical performance of ATI and CAP using optimal measurement cutoff values

![](ct9-10-e00081-g005)

Figure [4](#F4){ref-type="fig"} shows the ROCs for S \> 0 and S \> 1 of the ATI and CAP techniques. For S \> 1, a statistically significant improvement (*P* = 0.04) in the AUROC was observed for ATI (0.95) with respect to CAP (0.88), whereas the slight improvement in the AUROC of ATI for S \> 0 was not significant (*P* = 0.14).

![Comparison of receiver operating characteristic curves for ATI and CAP for S0 vs S1-S3, as defined by MRI-PDFF ≥ 5%, and S0-S1 vs S2-S3, as defined by MRI-PDFF ≥ 16.3%. ATI, attenuation imaging; AUROC, area under the receiver operating characteristic (curve); CAP, controlled attenuation parameter; PDFF, proton density fat fraction.](ct9-10-e00081-g006){#F4}

Concordance of ATI and MRI-PDFF in grading liver steatosis {#s3-3}
----------------------------------------------------------

The agreement between the 2 techniques was 63.1% with a Cohen kappa coefficient of 0.47. Table [3](#T3){ref-type="table"} reports the number of misclassified cases.

###### 

Grading of liver steatosis with ATI vs the grading with MRI-PDFF

![](ct9-10-e00081-g007)

DISCUSSION {#s4}
==========

The results of this study show that ATI is more accurate than CAP for detecting and quantifying liver steatosis, and this difference is statistically significant for S \> 1. CAP was the first US-based tool available for the quantification of liver steatosis, and it has become a point-of-care technique ([@R12],[@R24]). Studies that have compared the performance of the CAP to that of MRI-PDFF have shown that this latter is significantly more accurate for the grading of liver steatosis ([@R25]--[@R28]).

The advantage of ATI is that it is implemented in an US system; thus, a morphological evaluation of the liver and the assessment of its biomechanical properties, i.e., liver stiffness, are possible together with the quantification of liver steatosis. This multiparametric approach can help reducing costs in the evaluation of patients with chronic liver disease. Using ATI, the attenuation is color coded; thus, it is possible to visualize areas of artefacts and avoid including them in the measurement box. These features may contribute to the better performance of ATI compared to CAP, and to a reproducibility of measurements higher than that reported with CAP ([@R29],[@R30]).

A recent meta-analysis has proposed a cutoff of CAP for S \> 0 that is slightly lower with respect to the one we found in our study, even though it was suggested to adjust it to several covariates ([@R12]). Analyzing the data using the cutoff proposed by the meta-analysis, i.e., 248 dB/m, or the cutoff proposed by Caussy et al. ([@R19]), i.e., 288 dB/m, there was an increase of misclassified cases (data not shown). On the other hand, the moderate agreement of the CAP with the reference standard did not allow a more detailed analysis. We observed an increase of the AUROC of the CAP when only the values with an IQR \< 40 dB/m were analyzed; however, this criterion was fulfilled in less than 2 thirds of the cases (see Table, Supplemental Digital Content 5, <http://links.lww.com/CTG/A99>, which shows the results of the statistical analysis). This finding is in agreement with that of a recent study and may raise concerns on the applicability of the CAP technique in patients with NAFLD ([@R19]).

We have observed a higher repeatability of the ATI measurements with respect to that reported for the CAP, and this may be an advantage in longitudinal studies and for the follow-up of patients with NAFLD.

NAFLD is becoming a major health problem with a global estimated prevalence of 25.24% ([@R1]). It is associated with several metabolic comorbidities that are the risk factors for cardiovascular diseases and may progress to nonalcoholic steatohepatitis (NASH) ([@R31]). Thus, an early and accurate detection of liver steatosis is of outmost importance in this scenario. The results of this study show that ATI is a very valuable biomarker, showing an AUROC of 0.91 for the detection of liver steatosis. Currently, several treatments for NAFLD and NASH are in phase 3 trials and seem promising. A recent study has shown that significant steatosis is associated with fibrosis progression in patients with NAFLD ([@R32]). Therefore, an accurate noninvasive grading of steatosis is of great interest. MRI-PDFF is the accepted reference standard for the evaluation of liver steatosis. The advantages of using an US-based technique are the lower costs and the wider availability of the US systems. On this regard, ATI seems a very promising tool, showing an AUROC of 0.95 for the diagnosis of significant steatosis (S0-S1 vs S2-S3). However, the agreement between the grading of liver steatosis with ATI and with MRI-PDFF was only moderate. This is a pilot study in which consecutive patients were enrolled, thus an uneven distribution of different grade of liver steatosis was inevitable. In fact, in our series 65 of 123 (52.8%) patients had mild steatosis (S1). The relatively small number of patients in our series may also account for this finding. On the other hand, this new technique may need further improvement to amplify the range of values for better defining S \> 1 steatosis.

Our cohort comprised patients at risk of liver steatosis; thus, it was not a well-defined series of patients with NAFLD/NASH. We also included healthy volunteers to obtain ATI cutoffs that could be applicable for screening purpose in a population at risk of steatosis. The selection bias is unavoidable, and it is even higher when only patients with a definitive diagnosis of NAFLD or NASH are studied. For screening purpose in a population at risk of NAFLD, our study shows that ATI seems a valid tool.

There are some limitations to this study. First, this was a single-center study; thus, the results may not be applicable to the general population. However, this was a pilot study aimed at assessing the diagnostic performance of a new US software for the quantification of liver steatosis. Second, liver biopsy was not performed. However, MRI-PDFF has become the reference standard for the quantification of fat in the liver, and there was not any clinical indication for liver biopsy in our series of patients. Third, our patients had none or little fibrosis; thus, we did not explore whether significant fibrosis can affect the accuracy of the technique. Fourth, the small number of individuals in this pilot study did not allow a correct analysis of the performance of ATI for S \> 2. On this regard, further studies in large series are needed, because patients with severe steatosis are the most relevant clinically. Fifth, the study was conducted in a referral center and the examinations were conducted by expert operators, and this context could have led to better results. Finally, we should acknowledge that the ATI cutoffs were derived from a rather artificial setting and, therefore, they cannot easily be used for clinical purposes. Larger studies focusing on a real screening scenario are needed.

In conclusion, ATI seems a reliable and accurate tool for the assessment of liver steatosis. It performs better than CAP, and this improvement is statistically significant for S \> 1. In our cohort, there was a high prevalence of no fibrosis/mild fibrosis; thus, further studies are needed to evaluate whether the accuracy of ATI in grading steatosis is affected by the stage of liver fibrosis.
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